Clinical Observation of Buzhong Yiqi Decoction Plus Acupoint Intradermal Needling Combined with Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma

Abstract

Abstract: Objective To explore the clinical efficacy of Buzhong Yiqi Decoction plus acupoint intradermal needling combined with chemotherapy for advanced and driver gene test negative lung adenocarcinoma. Methods A total of 60 patients with advanced unresectable lung adenocarcinoma who were treated in Xu Yi People's Hospital from January 2020 to December 2021. They were randomly divided into two groups, the observation group and the control group. The control group was treated with standard western medicine chemotherapy and immunotherapy, and the treatment group was treated with the control group Combined with Buzhong Yiqi Decoction Modified Recipe and acupoint intradermal needling, improvement of clinical symptoms, quality of life score, tumor marker level and adverse reactions of the two groups were observed. Results The improvement rates of chest tightness, fatigue and anorexia in the treatment group were significantly higher than those in the control group (P<0.05); the KPS scores of the quality of life after treatment were improved compared with those before treatment (P<0.05), but the KPS of the treatment group after treatment was better than the control group (P<0.05); after treatment, the serum CEA and CYFRA21-1 values in the treament group decreased more than those in the control group (P<0.05); the incidence of dizziness, nausea, vomiting and bone marrow suppression in the control group was significantly higher than that in the treament group (P<0.05). Conclusion In the treatment of advanced unresectable and driver gene test negative lung adenocarcinoma patients, on the basis of conventional chemotherapy and immunotherapy, combined with Buzhong Yiqi Decoction plus acupoint intradermal needling can effectively relieve the clinical symptoms of patients, improve the quality of life and reduce the Toxic effects caused by chemotherapy, so have promotion value.

Key words: advanced lung adenocarcinoma, buzhong yiqi decoction, acupoint intradermal needling, clinical efficacy, toxic reaction

CLC Number:

R734

DING Zhen-yang, U Fang, ZHU Fei, CHEN Feng, SUN Zi-kai, REN Zhan-liang, QU Chen-xue. Clinical Observation of Buzhong Yiqi Decoction Plus Acupoint Intradermal Needling Combined with Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(3): 4-8.

References

[1] Sung H, Ferlay J, Siegel R L, et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[2] Allemani C, Matsuda T, Di Carlo V, et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3):analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet,2018,391(10125):1023-1075.
[3] Lu S, Cheng Y, Zhou C C, et al.Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer[J]. Clin Lung Cancer,2016,17(5):103-112.
[4] 徐杉智,余功,谢斌.肺癌的病机分析及方剂应用探索[J].辽宁中医杂志,2018,45(2):270-272.
[5] 李东垣. 内外伤辨惑论[M].北京:中国医药科技出版社,2011:15-16.
[6] 中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2018版)[J].中华肿瘤杂志,2018,40(12):935-964.
[7] 余小萍,方祝元.中医内科学(第3版)[M].上海:上海科学技术出版社,2018:353-364.
[8] 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:2,5,7.
[9] 张培形,于明薇,杨宗艳,等.中晚期非小细胞肺癌中西医疗效评价方法比较研究[J].中国中西医结合杂志,2010,30(7):702-705.
[10] 李燕星,张光霁,阮善明,等.非小细胞肺癌不同时期的中医治法[J].中华中医药杂志,2018,33(8):3532-3534.
[11] Gadgeel S, Rodríguez-Abreu D, Speranza G, et al.Updated Analysis From KEYNOTE-189:Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer[J]. J Clin Oncol,2020,38(14):1505-1517.
[12] Nasser N J, Gorenberg M, Agbarya A.First line Immunotherapy for Non-Small Cell Lung Cancer[J]. Pharmaceuticals (Basel),2020,13(11):373.
[13] 王学谦,侯炜,郑佳彬,等.中医综合治疗方案维持治疗晚期非小细胞肺癌的多中心、大样本、前瞻性队列研究[J].中医杂志,2020, 61(8):690-694.
[14] 张博,李雁.肺癌可从胸痹论治[J].辽宁中医杂志,2020,47(12):54-56.
[15] 谢卓恩. 补中益气汤加味治疗脾胃虚弱型慢性萎缩性胃炎的临床疗效观察[D].南宁:广西中医药大学,2018:31-34.
[16] 徐国品. 补中益气汤改善肺脾气虚型晚期非小细胞肺癌患者生活质量的临床研究[D].合肥:安徽中医药大学,2019:25-27.
[17] Park B, You S, Cho W C S, et al. A systematic review of herbal medicines for the treatment of cancer cachexia in animal models[J]. J Zhejiang Univ Sci B,2019,20(1):9-22.
[18] 唐倩,廖大忠,李修元.皮内针联合西药治疗肿瘤化疗后恶心呕吐的临床研究[J].中医药学报,2018,46(5):54-57.
[19] 赵兰风,马洪举,曾科学,等.针刺改善肿瘤放化疗术后白细胞减少症的临床观察[J].辽宁中医杂志,2019,46(7):1521-1522.